← Back to headlines
Sanofi's Nexviazyme Achieves Primary Goal in Pompe Disease Study
Sanofi announced that its drug Nexviazyme successfully met its primary endpoint in a clinical study for Pompe disease, marking a significant development for the treatment.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
